|
News Genzyme Reports Top-line Results for TENERE Study of Oral Teriflunomide in Relapsing Multiple Sclerosis
Genzyme, a Sanofi company, reported top-line results from TENERE, a Phase III clinical trial comparing the effectiveness, safety and tolerability of once-daily oral teriflunomide to interferon beta-1a (Rebif®), an approved injectable therapy, in people with relapsing forms of multiple sclerosis (RMS). |
|
News Phase II Study Showed Ocrelizumab Maintained Significant Reduction in Disease Activity for Multiple Sclerosis Patients for Almost Two Years
Genentech, a member of the Roche Group announced 96-week results1 from a Phase II study of ocrelizumab in patients with relapsing-remitting multiple sclerosis (RRMS), the most common clinical form of the disease. |
|
News ELEASE DETAILS Print Current | Archive Biogen Idec Announces Positive Top-Line Results from Second Phase 3 Trial Investigating Oral BG-12 in Multiple Sclerosis
Biogen Idec announced positive top-line results from CONFIRM, the second of two pivotal Phase 3 clinical trials designed to evaluate the investigational oral compound BG-12 (dimethyl fumarate) in people with relapsing-remitting multiple sclerosis (RRMS). |
|
News Oral Therapy Teriflunomide (Aubagio) Significantly Reduces Relapses Leading to Hospitalization of Patients with Multiple Sclerosis
Sanofi and its subsidiary Genzyme announced new data from the pivotal TEriflunomide Multiple Sclerosis Oral (TEMSO) Phase III trial showing that once-daily oral teriflunomide significantly reduced annualized rates of relapses leading to hospitalization. |
|
News Alemtuzumab (Lemtrada) Significantly Reduces Relapses in Multiple Sclerosis vs Interferon Beta-1a in a Phase III Study
Sanofi and its subsidiary Genzyme announced new results from the CARE-MS I trial, the first of two randomized, Phase III clinical trials comparing the investigational drug alemtuzumab (Lemtrada) to Rebif |
|
News Biogen Idec and Abbott Announce Positive Top-Line Results from the First Registrational Trial for Daclizumab HYP in Relapsing-Remitting Multiple Sclerosis
Biogen Idec and Abbott announced positive top-line results from SELECT, a global, registrational Phase 2b clinical trial designed to evaluate the investigational compound daclizumab high-yield process (DAC HYP) in people with relapsing-remitting multiple sclerosis (RRMS) over one year. |
|
News Results of Phase III BRAVO Trial Reinforce Unique Profile of Laquinimod for multiple Sclerosis Treatment
Teva Pharmaceutical Industries Ltd. and Active Biotech announced initial results from the Phase III BRAVO study, which was designed to evaluate the efficacy, safety and tolerability of oral laquinimod compared to placebo and to provide a benefit-risk assessment comparing oral laquinimod and a reference arm of injectable Interferon-1a (Avonex®). |
|
Leaflet Drug Fampyra
Fampyra is a medicine that contains the active substance fampridine. It is available as prolonged-release tablets (10 mg). |
|
News Sanofi Reports Positive Top-Line Results from First Phase 3 Study of Alemtuzumab (Lemtrada) in Multiple Sclerosis
Sanofi and its subsidiary Genzyme announced positive top-line results from CARE-MS I, the first of two randomized, Phase 3 clinical trials comparing the investigational drug alemtuzumab to the approved multiple sclerosis therapy Rebif® (high dose subcutaneous interferon beta-1a) in patients with relapsing-remitting multiple sclerosis (RRMS). |
|
News ELEASE DETAILS Print Current | Archive Biogen Idec Receives Conditional Approval in the European Union for FAMPYRA to Improve Walking in Adults with Multiple Sclerosis
Biogen Idec announced it has received conditional approval from the European Commission for FAMPYRA(R) (prolonged-release fampridine tablets) to improve walking in adult patients with multiple sclerosis (MS) who have walking disability (Expanded Disability Status Scale 4-7). |
|
News Teva Completes Enrollment in Phase III Multiple Sclerosis Trial Evaluating Glatiramer Acetate Three Times Weekly
Teva Pharmaceutical Industries Ltd. ( announced completion of patient enrollment for the GALA (Glatiramer Acetate Low-frequency Administration) trial. |
|
News Proteostasis Therapeutics & Elan Form Drug Discovery Initiative
Proteostasis Therapeutics ("Proteostasis") and Elan Corporation announced a strategic business relationship to advance Proteostasis` platform for the discovery and development of disease-modifying, small molecule drugs |
|
News Teva Pharmaceutical Industries Ltd. Makes Statement on DEFINE Study Results
We acknowledge the results of the DEFINE study seem promising for patients. It is important to note that as a general rule, results obtained in clinical trials in multiple sclerosis (MS) cannot be compared, unless agents are tested in a head-to-head manner in the same trial. |
|
News Five-year Alemtuzumab Phase 2 Data Shows Large Percentage of MS Patients Remain Free of Clinically-Active Disease
Genzyme Corp., a subsidiary of sanofi-aventis Group, reported additional five-year patient data from its completed Phase 2 multiple sclerosis (MS) trial showing that nearly two-thirds of alemtuzumab treated patients remained free of clinically-active disease as much as four years after most patients received their last course of the investigational drug. |
|
News Additional Study Data Showed 70 Percent of Patients had Improved or Stabilized Cognition Following Treatment with Copaxone
Teva Pharmaceutical Industries Ltd. announced preliminary data from two studies, Coptimize and QualiCop. |
|
News Genzyme Presents New Data from Alemtuzumab Phase 2 MS Trial at 63rd Annual Meeting of the American Academy Of Neurology
Genzyme, a subsidiary of sanofi-aventis Group, announced that it will present new data from its completed Phase 2 trial of the investigational drug alemtuzumab for multiple sclerosis (MS) at the American Academy of Neurology`s (AAN) 63rd Annual Meeting in Hawaii. |
|
Leaflet Drug Gilenya
Gilenya is a medicine that contains the active substance fingolimod. It is available as capsules (0.5 mg). |
|
News Biogen Idec Receives Negative Opinion from the CHMP on FAMPYRA
Biogen Idec announced that the European Medicines Agency`s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a negative opinion recommending against approval of FAMPYRA(R) (prolonged-release fampridine 10 mg tablets) to improve walking ability in adult patients with multiple sclerosis (MS) in the European Union. Biogen Idec intends to appeal this opinion and request a re-examination of the decision by the CHMP. |
|
News Teva Files Citizen Petition Surrounding Purported Generic Version of Copaxone
Teva Pharmaceutical Industries Ltd. announced that the company has filed a Citizen Petition (CP) with the U.S. Food and Drug Administration (FDA) requesting that the FDA refuse to approve any abbreviated new drug application (ANDA) for a purported generic version of COPAXONE® (glatiramer acetate injection). |
|
News Teva Announces Successful Results of Phase III Study with Oral Laquinimod For Multiple Sclerosis
Teva Pharmaceutical Industries Ltd. and Active Biotech announced initial results from the two-year Phase III ALLEGRO study, which demonstrated that relapsing-remitting multiple sclerosis (MS) patients treated with 0.6 mg daily oral laquinimod experienced a statistically significant reduction in annualized relapse rate compared to placebo. |
|
News Biogen Idec Awards Clinical Fellowship Program Grants to Support Education and Research for the Treatment of Multiple Sclerosis
As part of its commitment to furthering the quality of education in the field of multiple sclerosis, Biogen Idec is proud to announce that it provided grants to twelve prestigious universities and medical centers across the country for the 2010-2011 academic year. |
|
News Phase II Study with Ocrelizumab Shows Significant Reduction in Disease Activity for Multiple Sclerosis Patients
Genentech, Inc. and Biogen Idec today announced 24-week results1 from a phase II study of ocrelizumab in patients with relapsing-remitting multiple sclerosis (RRMS), the most common form2 of the disease. |
|
News ELEASE DETAILS current archive inks Print Current | Archive Data Further Supporting Anti-JC Virus Antibody Assay Presented at the 26th Congress of the European Committee for Treatment and Research in Multiple Sclerosis
Biogen Idec and Elan Corporation, plc announced data further supporting the potential clinical utility of an investigational assay that detects anti-JC virus (JCV) antibodies in human plasma or serum. |
|
Article Multiple Sclerosis
Multiple sclerosis (MS) is a nervous system disease that affects your brain and spinal cord. |
|
Article Multiple Sclerosis International Federation
The Multiple Sclerosis International Federation (MSIF) was established in 1967 as an international body linking the activities of national MS societies around the world. |
